Parnell Pharmaceuticals Stock Forecast, Price & News

+0.02 (+25.00 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume177 shs
Average Volume4,103 shs
Market Capitalization$2 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PARNF News and Ratings via Email

Sign-up to receive the latest news and ratings for Parnell Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Parnell Pharmaceuticals logo

About Parnell Pharmaceuticals

Parnell Pharmaceuticals Holdings Ltd. operates as a veterinary pharmaceutical company. The firm engages in the development, manufacture and commercializing animal health solutions. It operates through the following segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World and Manufacturing Operations. The Companion Animal segment sells osteoarthritis suite of products Zydax, Glyde and Tergive for canine and equine species. The Production Animal-U.S. segment includes reproductive hormone portfolio across production animals. The Production Animal-Rest of World segment provides reproductive hormone products outside of the U.S. The Manufacturing Operations segment involves in sterile manufacturing and release of pharmaceutical products. The company was founded on June 25, 2009 and is headquartered in Sydney, Australia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Parnell Pharmaceuticals (OTCMKTS:PARNF) Frequently Asked Questions

What stocks does MarketBeat like better than Parnell Pharmaceuticals?

Wall Street analysts have given Parnell Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Parnell Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Parnell Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Parnell Pharmaceuticals' stock was trading at $0.1001 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PARNF stock has decreased by 0.1% and is now trading at $0.10.
View which stocks have been most impacted by COVID-19

Who are Parnell Pharmaceuticals' key executives?

Parnell Pharmaceuticals' management team includes the following people:
  • Brad R. McCarthy, CEO, CFO, Secretary & Executive Director
  • Leonardo Avendano, Vice President-Manufacturing
  • Lee Whaley, Vice President-Regulatory

Who are some of Parnell Pharmaceuticals' key competitors?

What is Parnell Pharmaceuticals' stock symbol?

Parnell Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PARNF."

How do I buy shares of Parnell Pharmaceuticals?

Shares of PARNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Parnell Pharmaceuticals' stock price today?

One share of PARNF stock can currently be purchased for approximately $0.10.

How much money does Parnell Pharmaceuticals make?

Parnell Pharmaceuticals has a market capitalization of $2 million.

How many employees does Parnell Pharmaceuticals have?

Parnell Pharmaceuticals employs 78 workers across the globe.

What is Parnell Pharmaceuticals' official website?

The official website for Parnell Pharmaceuticals is www.parnell.com.

Where are Parnell Pharmaceuticals' headquarters?

Parnell Pharmaceuticals is headquartered at UNIT 4 CENTURY ESTATE 476 GARDENERS ROAD, ALEXANDRIA C3, 2015.

How can I contact Parnell Pharmaceuticals?

Parnell Pharmaceuticals' mailing address is UNIT 4 CENTURY ESTATE 476 GARDENERS ROAD, ALEXANDRIA C3, 2015. The company can be reached via phone at (129) 667-4411 or via email at [email protected].

This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.